Newsroom | 5731 results

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the pricing of an underwritten public offering of 20,588,236 common shares, without par value, at a public offering price of $34.00 per common share. The gross proceeds to Definium from the offering, before de...

MIAMI & HOUSTON--(BUSINESS WIRE)--The Society for Neuro-Oncology (SNO), the world's largest multidisciplinary organization dedicated to advancing research, education, and clinical care for patients with brain and spinal cord tumors, and OpenEvidence, the leading AI-powered clinical decision support platform, today announced a landmark partnership, designating OpenEvidence as SNO's official generative AI partner. As part of the collaboration, SNO will embed OpenEvidence across its member-facing...

LOS ANGELES--(BUSINESS WIRE)--Children’s Hospital Los Angeles Receives up to $17.2 Million Grant to Advance Autism Research...

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years of dedicated service and leadership. “On behalf of the entire Board of Directors, we are...

HOUSTON--(BUSINESS WIRE)--For millions of people living with the long-term effects of traumatic brain injury (TBI), the prevailing belief has been that chronic neuroinflammation causes recovery to plateau over time, meaning correspondingly few long-range care options. New research published in the prestigious journal Brain, one of the world’s leading neurology journals, is challenging that assumption. “Our findings suggest that chronic neuroinflammation may be a treatable target, even years aft...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026...

CAMBRIDGE, England--(BUSINESS WIRE)--TRIMTECH Therapeutics (TRIMTECH or the Company), a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in seed funding, bringing the total for the round to $47 million (£35 million). The financing was led by Johnson & Johnson’s corporate venture capital organization, Johnson & Johnson Innovation –...

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it intends to offer and sell, subject to market conditions, $500 million of its common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. I...

MANHASSET, N.Y.--(BUSINESS WIRE)--The Feinstein Institutes for Medical Research, the home of medical research at the Northeast’s largest non-profit health system Northwell Health, today announced that its two peer-reviewed, open-access scientific journals have reached significant milestones, reflecting the strength, quality and global influence of the research they publish. Molecular Medicine, published in collaboration with Springer Nature’s BioMed Central, has achieved its highest impact fact...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Trace Neuroscience, Inc., a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases, today announced the initiation of its global clinical development program for TRCN-1023, an investigational antisense oligonucleotide (ASO) designed to restore UNC13A protein function for the treatment of amyotrophic lateral sclerosis (ALS). The global TRCN-1023 clinical program includes the Phase 1/2 FUN...